Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of C4 Therapeutics, Inc. (CCCC) since 2020 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of C4 Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1662579.
Total stock buying since 2020: $336,287.
Total stock sales since 2020: $16,867,071.
Total stock option exercises since 2020: $946,852.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 0 | $0 | 0 | $0 | 46,250 | $0 |
| 2023 | 5,667 | $31,735 | 0 | $0 | 53,750 | $0 |
| 2022 | 10,000 | $84,000 | 15,000 | $481,844 | 70,395 | $231,997 |
| 2021 | 0 | $0 | 353,052 | $16,385,227 | 131,657 | $672,823 |
| 2020 | 11,608 | $220,552 | 0 | $0 | 14,444 | $42,032 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2024-11 | 0 | $0 | 0 | $0 | 27,500 | $0 |
| 2024-09 | 0 | $0 | 0 | $0 | 18,750 | $0 |
| 2023-08 | 0 | $0 | 0 | $0 | 18,750 | $0 |
| 2023-02 | 5,667 | $31,735 | 0 | $0 | 0 | $0 |
| 2023-01 | 0 | $0 | 0 | $0 | 35,000 | $0 |
| 2022-07 | 0 | $0 | 0 | $0 | 1,424 | $5,048 |
| 2022-05 | 0 | $0 | 0 | $0 | 23,750 | $0 |
| 2022-04 | 10,000 | $84,000 | 0 | $0 | 28,084 | $122,024 |
| 2022-01 | 0 | $0 | 15,000 | $481,844 | 17,137 | $104,925 |
| 2021-12 | 0 | $0 | 755 | $22,838 | 25,562 | $106,473 |
| 2021-11 | 0 | $0 | 755 | $30,283 | 0 | $0 |
| 2021-10 | 0 | $0 | 15,755 | $711,764 | 25,000 | $139,600 |
| 2021-09 | 0 | $0 | 159,895 | $7,937,214 | 12,500 | $62,250 |
| 2021-08 | 0 | $0 | 54,580 | $2,455,521 | 0 | $0 |
| 2021-07 | 0 | $0 | 104,802 | $4,607,819 | 42,500 | $234,450 |
| 2021-06 | 0 | $0 | 755 | $28,078 | 0 | $0 |
| 2021-05 | 0 | $0 | 755 | $28,025 | 0 | $0 |
| 2021-04 | 0 | $0 | 15,000 | $563,685 | 15,711 | $100,020 |
| 2021-02 | 0 | $0 | 0 | $0 | 8,836 | $25,283 |
| 2021-01 | 0 | $0 | 0 | $0 | 1,548 | $4,747 |
| 2020-12 | 0 | $0 | 0 | $0 | 14,444 | $42,032 |
| 2020-10 | 11,608 | $220,552 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-11-07 | Adams Kendra (Chief Financial Officer) | Option Ex | 3,750 | .00 | 0 |
| 2024-11-07 | Boyle Scott N (Chief Business Officer) | Option Ex | 3,750 | .00 | 0 |
| 2024-11-07 | Schick Kelly (Chief People Officer) | Option Ex | 3,750 | .00 | 0 |
| 2024-11-07 | Siegel Jolie (Chief Legal Officer) | Option Ex | 3,750 | .00 | 0 |
| 2024-11-07 | Hirsch Andrew (President & CEO) | Option Ex | 12,500 | .00 | 0 |
| 2024-09-16 | Adams Kendra (Chief Financial Officer) | Option Ex | 2,250 | .00 | 0 |
| 2024-09-16 | Boyle Scott N (Chief Business Officer) | Option Ex | 2,250 | .00 | 0 |
| 2024-09-16 | Fisher Stewart (Chief Scientific Officer) | Option Ex | 2,250 | .00 | 0 |
| 2024-09-16 | Schick Kelly (Chief People Officer) | Option Ex | 2,250 | .00 | 0 |
| 2024-09-16 | Siegel Jolie (Chief Legal Officer) | Option Ex | 2,250 | .00 | 0 |
| 2024-09-16 | Hirsch Andrew (President & CEO) | Option Ex | 7,500 | .00 | 0 |
| 2023-08-30 | Boyle Scott N (Chief Business Officer) | Option Ex | 2,250 | .00 | 0 |
| 2023-08-30 | White Lauren (Chief Financial Officer) | Option Ex | 2,250 | .00 | 0 |
| 2023-08-30 | Fisher Stewart (Chief Scientific Officer) | Option Ex | 2,250 | .00 | 0 |
| 2023-08-30 | Schick Kelly (Chief People Officer) | Option Ex | 2,250 | .00 | 0 |
| 2023-08-30 | Siegel Jolie (Chief Legal Officer) | Option Ex | 2,250 | .00 | 0 |
| 2023-08-30 | Hirsch Andrew (President & CEO) | Option Ex | 7,500 | .00 | 0 |
| 2023-02-08 | Koppikar Utpal | Buy | 5,667 | 5.60 | 31,735 |
| 2023-01-30 | Boyle Scott N (Chief Business Officer) | Option Ex | 3,750 | .00 | 0 |
| 2023-01-30 | White Lauren (Chief Financial Officer) | Option Ex | 3,750 | .00 | 0 |
| 2023-01-30 | Crystal Adam (Chief Medical Officer) | Option Ex | 3,750 | .00 | 0 |
| 2023-01-30 | Fisher Stewart (Chief Scientific Officer) | Option Ex | 3,750 | .00 | 0 |
| 2023-01-30 | Schick Kelly (Chief People Officer) | Option Ex | 3,750 | .00 | 0 |
| 2023-01-30 | Siegel Jolie (Chief Legal Officer) | Option Ex | 3,750 | .00 | 0 |
| 2023-01-30 | Hirsch Andrew (President & CEO) | Option Ex | 12,500 | .00 | 0 |
| 2022-07-15 | Anderson Kenneth Carl (Director) | Option Ex | 1,424 | 3.54 | 5,048 |
| 2022-05-25 | Boyle Scott N (Chief Business Officer) | Option Ex | 3,750 | .00 | 0 |
| 2022-05-25 | Fisher Stewart (Chief Scientific Officer) | Option Ex | 3,750 | .00 | 0 |
| 2022-05-25 | Siegel Jolie (Chief Legal Officer) | Option Ex | 3,750 | .00 | 0 |
| 2022-05-25 | Hirsch Andrew (President & CEO) | Option Ex | 12,500 | .00 | 0 |
| 2022-04-12 | Fisher Stewart (Chief Scientific Officer) | Option Ex | 28,084 | 4.34 | 122,024 |
| 2022-04-12 | Hirsch Andrew (President & CEO) | Buy | 10,000 | 8.40 | 84,000 |
| 2022-01-26 | Anderson Kenneth Carl (Director) | Option Ex | 2,137 | 3.54 | 7,575 |
| 2022-01-04 | Crystal Adam (Chief Medical Officer) | Sale | 15,000 | 32.12 | 481,844 |
| 2022-01-04 | Crystal Adam (Chief Medical Officer) | Option Ex | 15,000 | 6.49 | 97,350 |
| 2021-12-22 | Crystal Adam (Chief Medical Officer) | Option Ex | 5,000 | 6.49 | 32,450 |
| 2021-12-17 | Salter Malcolm (Director) | Sale | 755 | 30.25 | 22,838 |
| 2021-12-08 | Fisher Stewart (Chief Scientific Officer) | Option Ex | 20,562 | 3.60 | 74,023 |
| 2021-11-19 | Salter Malcolm (Director) | Sale | 755 | 40.11 | 30,283 |
| 2021-10-15 | Salter Malcolm (Director) | Sale | 755 | 44.94 | 33,929 |
| 2021-10-08 | Crystal Adam (Chief Medical Officer) | Option Ex | 10,000 | 6.49 | 64,900 |
| 2021-10-01 | Crystal Adam (Chief Medical Officer) | Sale | 15,000 | 45.19 | 677,835 |
| 2021-10-01 | Crystal Adam (Chief Medical Officer) | Option Ex | 15,000 | 4.98 | 74,700 |
| 2021-09-27 | Prokupets Elena (Director) | Sale | 1,850 | 50.04 | 92,570 |
| 2021-09-24 | Prokupets Elena (Director) | Sale | 3,015 | 50.11 | 151,072 |
| 2021-09-23 | Prokupets Elena (Director) | Sale | 19,180 | 50.72 | 972,713 |
| 2021-09-22 | Prokupets Elena (Director) | Sale | 10,548 | 50.10 | 528,423 |
| 2021-09-21 | Prokupets Elena (Director) | Sale | 10,321 | 50.14 | 517,463 |
| 2021-09-17 | Salter Malcolm (Director) | Sale | 755 | 49.89 | 37,666 |
| 2021-09-17 | Prokupets Elena (Director) | Sale | 10,840 | 50.05 | 542,487 |
| 2021-09-16 | Prokupets Elena (Director) | Sale | 26,499 | 49.55 | 1,312,945 |
| 2021-09-15 | Prokupets Elena (Director) | Sale | 54,193 | 48.84 | 2,646,677 |
| 2021-09-14 | Prokupets Elena (Director) | Sale | 984 | 50.02 | 49,216 |
| 2021-09-13 | Prokupets Elena (Director) | Sale | 6,660 | 50.07 | 333,472 |
| 2021-09-10 | Prokupets Elena (Director) | Sale | 2,550 | 50.00 | 127,510 |
| 2021-09-10 | Siegel Jolie (Chief Legal Officer) | Sale | 12,500 | 50.00 | 625,000 |
| 2021-09-10 | Siegel Jolie (Chief Legal Officer) | Option Ex | 12,500 | 4.98 | 62,250 |
| 2021-08-20 | Salter Malcolm (Director) | Sale | 755 | 40.73 | 30,751 |
| 2021-08-03 | Fisher Stewart (Chief Scientific Officer) | Sale | 17,057 | 45.02 | 767,820 |
| 2021-08-03 | Prokupets Elena (Director) | Sale | 14,407 | 45.16 | 650,591 |
| 2021-08-02 | Fisher Stewart (Chief Scientific Officer) | Sale | 18,104 | 45.00 | 814,752 |
| 2021-08-02 | Prokupets Elena (Director) | Sale | 4,257 | 45.01 | 191,607 |
| 2021-07-29 | Crystal Adam (Chief Medical Officer) | Sale | 15,000 | 45.00 | 675,000 |
| 2021-07-29 | Crystal Adam (Chief Medical Officer) | Option Ex | 15,000 | 4.98 | 74,700 |
| 2021-07-29 | Fisher Stewart (Chief Scientific Officer) | Sale | 50,211 | 45.00 | 2,259,645 |
| 2021-07-29 | Prokupets Elena (Director) | Sale | 11,336 | 45.00 | 510,165 |
| 2021-07-29 | Siegel Jolie (Chief Legal Officer) | Sale | 12,500 | 45.00 | 562,500 |
| 2021-07-29 | Siegel Jolie (Chief Legal Officer) | Option Ex | 12,500 | 4.98 | 62,250 |
| 2021-07-16 | Salter Malcolm (Director) | Sale | 755 | 37.37 | 28,214 |
| 2021-07-01 | Crystal Adam (Chief Medical Officer) | Sale | 15,000 | 38.15 | 572,295 |
| 2021-07-01 | Crystal Adam (Chief Medical Officer) | Option Ex | 15,000 | 6.50 | 97,500 |
| 2021-06-18 | Salter Malcolm (Director) | Sale | 755 | 37.19 | 28,078 |
| 2021-05-21 | Salter Malcolm (Director) | Sale | 755 | 37.12 | 28,025 |
| 2021-04-14 | Anderson Kenneth Carl (Director) | Option Ex | 711 | 3.54 | 2,520 |
| 2021-04-05 | Crystal Adam (Chief Medical Officer) | Sale | 15,000 | 37.58 | 563,685 |
| 2021-04-05 | Crystal Adam (Chief Medical Officer) | Option Ex | 15,000 | 6.50 | 97,500 |
| 2021-02-18 | Cohen Marc A (Director) | Option Ex | 536 | 2.11 | 1,130 |
| 2021-02-03 | Fisher Stewart (Chief Scientific Officer) | Option Ex | 8,300 | 2.91 | 24,153 |
| 2021-01-22 | Anderson Kenneth Carl (Director) | Option Ex | 1,548 | 3.07 | 4,747 |
| 2020-12-11 | Fisher Stewart (Chief Scientific Officer) | Option Ex | 14,444 | 2.91 | 42,032 |
| 2020-10-06 | Salter Malcolm (Director) | Buy | 1,315 | 19.00 | 24,985 |
| 2020-10-06 | Mckee William (Chief Financial Officer) | Buy | 5,263 | 19.00 | 99,997 |
| 2020-10-06 | Cohen Marc A (Director) | Buy | 5,030 | 19.00 | 95,570 |
Insider trading activities including stock purchases, stock sales, and option exercises of CCCC listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of C4 Therapeutics, Inc. (symbol CCCC, CIK number 1662579) see the Securities and Exchange Commission (SEC) website.